Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 22, 2026
Charles Schwab (SCHW) Delivers Record Q2 2026 Results with Strong Asset Growth

Charles Schwab (SCHW) Delivers Record Q2 2026 Results with Strong Asset Growth

Key Takeaways

  • Net revenues reached a record $7.1 billion, up 21% year-over-year.
  • GAAP earnings per share hit $1.54, up 43% from the prior year, with adjusted EPS of $1.62.
  • Core net new assets totaled $119.8 billion, a 49% increase versus Q2 2025.
  • Daily average trading volume set a record at 11.9 million trades, up 57% year-over-year.
  • Total client assets grew 22% to $13.08 trillion, with 1.4 million new brokerage accounts opened.
  • Net interest margin expanded to 3.00%, up 12 basis points quarter-over-quarter.

Putting the Results in Context

The Charles Schwab Corporation’s second-quarter results highlight the strength of its diversified business model amid elevated market volatility and client engagement. Strong trading activity, asset gathering, and net interest revenue growth underscore the company’s ability to capitalize on investor behavior. These outcomes build on prior quarters’ momentum, where client assets and activity have steadily expanded, positioning SCHW as a key beneficiary of broader market participation and shifts in client asset allocation.

The Reported Numbers

The Charles Schwab Corporation reported Q2 2026 net revenues of $7.072 billion, up 21% from $5.851 billion in Q2 2025 and exceeding analyst estimates. GAAP net income reached $2.8 billion, or $1.54 per diluted share, compared with $2.126 billion or $1.08 per share a year earlier. Adjusted net income was $2.9 billion, or $1.62 per share, after excluding $170 million in pre-tax transaction-related costs. Trading revenue rose 28% to $1.215 billion on record daily average trades of 11.9 million. Asset management and administration fees increased 16% to $1.825 billion. Bank loan balances grew 33% year-over-year to $67.0 billion, while margin loan balances climbed 30% quarter-over-quarter to $165.1 billion. Core net new assets of $119.8 billion surpassed expectations, and total client assets reached $13.08 trillion. I also checked industry comparisons using Tickeron’s AI Screener to see how these metrics stack up against peers.

Market Reaction and Investor Sentiment

Shares of The Charles Schwab Corporation rose following the July 21, 2026 earnings release, reflecting investor enthusiasm for the beat on both revenue and earnings alongside record trading volumes. Analysts highlighted the company’s resilience across interest-rate and market environments, with particular focus on client asset inflows and margin expansion. The results reinforced positive sentiment heading into the second half of the year. From what I see, this kind of broad-based strength often signals sustained momentum when client activity remains elevated.

Forward Outlook and Key Factors to Monitor

Investors will track guidance implications from management’s comments on client engagement and capital return strategies, including ongoing share repurchases. Continued monitoring of net interest margin trends, sweep cash balances, and growth in managed investing solutions remains important given seasonal and macroeconomic influences.

Key operating metrics such as daily average trades, core net new assets, and bank loan balances will provide insight into client activity levels. Broader industry dynamics, including regulatory developments and competitive positioning in wealth management, could also shape performance. I’m watching this closely as these factors tend to influence near-term performance.

Upcoming catalysts include the company’s Summer Business Update and the Q3 2026 earnings release scheduled for October 2026. Cost management efforts and integration of recent platform enhancements, such as new trading capabilities, warrant attention for their potential impact on expenses and revenue diversification.

Enhancing My Research with Tickeron Tools

When analyzing earnings releases like this one, I find it helpful to cross-reference key metrics with additional data points. Tickeron’s AI Screener allows me to quickly filter stocks and ETFs by technical patterns, fundamentals, and performance metrics. This helps confirm how SCHW stands relative to others in the sector without spending hours on manual checks. It is one of the tools I turn to for efficient idea generation and comparison during earnings season.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCHW

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SCHW's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SCHW turned positive on August 04, 2026. Looking at past instances where SCHW's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on SCHW as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for SCHW moved above the 200-day moving average on July 31, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHW advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 263 cases where SCHW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SCHW broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. SCHW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.737) is normal, around the industry mean (4.148). P/E Ratio (19.610) is within average values for comparable stocks, (20.994). Projected Growth (PEG Ratio) (1.083) is also within normal values, averaging (1.663). Dividend Yield (0.011) settles around the average of (0.033) among similar stocks. P/S Ratio (7.321) is also within normal values, averaging (31.056).

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13.14B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -14%. USDE experienced the highest price growth at 36%, while TOP experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -69%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 70
Price Growth Rating: 63
SMR Rating: 76
Profit Risk Rating: 86
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
SCHW
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of securities brokerage and other financial services

Industry InvestmentBanksBrokers

Profile
Details
Industry
Investment Banks Or Brokers
Address
3000 Schwab Way
Phone
+1 817 859-5000
Employees
33000
Web
https://www.aboutschwab.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.